<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>1844773</identifier>
<setSpec>0034-9887</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Tapia, R</dc:author>
<dc:author>Aguayo, R</dc:author>
<dc:author>Triantafilo, V</dc:author>
<dc:author>Palma, I</dc:author>
<dc:author>Pescio, S</dc:author>
<dc:author>Thompson, L</dc:author>
<dc:author>Castrillón, M</dc:author>
<dc:author>Silva, A</dc:author>
<dc:author>Azócar, G</dc:author>
<dc:author>Contreras, J</dc:author>
<dc:description xml:lang="en">Forty females (ages 15-74) with community-acquired, uncomplicated urinary tract infections were studied. Clinical and microbiological efficacy of cefuroxime (250 mg td) and trimethoprim sulfamethoxazole (160/800 mg td) used for 7 days were evaluated. The microorganisms found in the pre-treatment urinary cultures were: Escherichia Coli (85%), Klebsiella Pneumoniae (12.5%), and E. Agglomerans (2.5%). They were all susceptible to cefuroxime, and 42.5% were resistant to trimethoprim sulfamethoxazole (Kirby-Bauer). These findings show that trimethoprim sulfamethoxazole should not be used empirically while waiting for the results of urinary cultures, and that cefuroxime is a good alternative in these cases. Clinical cure was observed in all, and bacteriological cure in 75% of the pts treated with both antimicrobial agents. Relapses and reinfections were detected during follow-up emphasizing the importance of intra and post-treatment urinary cultures.</dc:description>
<dc:type>Clinical Trial</dc:type>
<dc:language>es</dc:language>
<dc:date>1991 Aug </dc:date>
<dc:title xml:lang="es">Tratamiento de las infecciones del tracto urinario no complicadas: cefuroximo versus cotrimoxazol.</dc:title>
<dc:title xml:lang="en">[Treatment of uncomplicated urinary tract infections: cefuroxime vs cotrimoxazole].</dc:title>
<dc:publisher>Revista medica de Chile</dc:publisher>
</metadata>
</record>
</pubmed-document>
